Digital repository of Slovenian research organisations

Show document
A+ | A- | Help | SLO | ENG

Title:Treatment with PCSK9 inhibitors influences microRNAs expression and changes of arterial wall properties : a randomized controlled trial
Authors:ID Rehberger Likozar, Andreja (Author)
ID Levstek, Tina (Author)
ID Karun, Tina (Author)
ID Trebušak Podkrajšek, Katarina (Author)
ID Zupan, Janja (Author)
ID Šebeštjen, Miran (Author)
Files:.pdf PDF - Presentation file, download (1,07 MB)
MD5: 382F46EBD975A23A343A387BE4CB5A0F
 
URL URL - Source URL, visit https://eurjmedres.biomedcentral.com/articles/10.1186/s40001-025-02398-6
 
Language:English
Typology:1.01 - Original Scientific Article
Organization:Logo UKC LJ - Ljubljana University Medical Centre
Abstract:Background: MicroRNAs (miRNAs) are involved in the synthesis of proprotein convertase subtilisin–kexin type 9 (PCSK9), one of the regulators of low-density lipoprotein cholesterol (LDL-C) metabolism, and are directly involved in the atherosclerotic process. The aim of this study was to verify whether treatment with PCSK9 inhibitors (PCSK9i) and changes in the expression of miRNAs involved in PCSK9 metabolism are associated with arterial wall properties in stable post-myocardial infarction (MI) patients with insufficiently regulated LDL-C levels and significantly increased Lp(a) levels. Methods: Ninety-five patients after MI were enrolled and randomized to a placebo (N = 31) or PCSK9i group (N = 64). The treatment group received subcutaneous alirocumab 150 mg or evolocumab 140 mg, every 2 weeks. Blood for biochemical and epigenetic analysis was taken and ultrasound measurements of flow-mediated dilation of brachial artery (FMD), carotid intima–media thickness (c-IMT) and pulse wave velocity (PWV) were performed initially and after 6 months of treatment. The expression of the selected 5 miRNAs (miR-191-5p, miR-224-5p, miR-337-3p, miR-483-5p, and miR-552-3p) was quantified using quantitative polymerase chain reaction. Results: A decrease in c-IMT was associated with a decrease in the expression of miR-337-3p (ρ = 0.329; p = 0.010) and miR-483-5p (ρ = 0.324; p = 0.012). We did not detect any associations between miRNA changes and FMD or PWV. Conclusions: Our results suggest that changes in the selected miRNAs are associated with changes in the morphological properties of the arterial wall. We have shown that the decrease in miR-483-5p expression present a good indicator of the regression of morphological atherosclerotic change. The trial registration: The study is registered with CinicalTrials under the number NCT04613167, date of registration November 2nd, 2020. Approval for this study was obtained from the National Medical Ethics Committee of the Republic of Slovenia (reference number: KME 0120-357/2018/8).
Keywords:miRNA, endothelial function, PCSK9 inhibitors, myocardial infarction, low-density lipoprotein cholesterol
Publication status:Published
Publication version:Version of Record
Year of publishing:2025
Number of pages:1 spletni vir (1 datoteka PDF ( 9 str.))
Numbering:Vol. 30, [article no.] 138
PID:20.500.12556/DiRROS-27664 New window
UDC:612.111:616.127-005.8
ISSN on article:2047-783X
DOI:10.1186/s40001-025-02398-6 New window
COBISS.SI-ID:231157507 New window
Note:Nasl. z nasl. zaslona; Opis vira z dne 2. 4. 2025;
Publication date in DiRROS:18.02.2026
Views:48
Downloads:17
Metadata:XML DC-XML DC-RDF
:
Copy citation
  
Share:Bookmark and Share


Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:European journal of medical research
Shortened title:Eur. j. med. res.
Publisher:I. Holzapfel, BioMed Central
ISSN:2047-783X
COBISS.SI-ID:523081753 New window

Document is financed by a project

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:P3-0308-2019
Name:Ateroskleroza in tromboza

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:P1-0170-2018
Name:Molekulski mehanizmi uravnavanja celičnih procesov v povezavi z nekaterimi boleznimi pri človeku

Funder:Other - Other funder or multiple funders
Funding programme:Univerzitetni klinični center Ljubljana
Project number:20240051
Name:Vpliv zaviralcev proproteina subtilisin-kexin konvertaze tip 9 (PCSK9) na izražanje genskih označevalcev vnetja in hemostaze pri bolnikih s koronarno boleznijo

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.

Secondary language

Language:Slovenian
Keywords:miRNA, endotelijska funkcija, zaviralci PCSK9, lipoprotein nizke gostote, holesterol


Back